Publications by authors named "Domitille Gras"

Introduction: Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurological disease usually described in adults. Expanded CAG repeats in the ATXN2 gene can lead to pediatric onset. This study aims to describe the natural history of SCA2 in children.

View Article and Find Full Text PDF

Background: Paroxysmal movement disorders are common in Glut1 deficiency syndrome (Glut1DS). Not all patients respond to or tolerate ketogenic diets.

Objectives: The objective was to evaluate the effectiveness and safety of triheptanoin in reducing the frequency of disabling movement disorders in patients with Glut1DS not receiving a ketogenic diet.

View Article and Find Full Text PDF

Background: Monoallelic pathogenic variants of often result in paroxysmal kinesigenic dyskinesia (PKD). Little is known about health-related quality of life (HrQoL), non-motor manifestations, self-esteem, and stigma in patients with PKD.

Objectives: We investigated non-motor symptoms and how they related to HrQoL in a genetically homogeneous group of -PKD patients.

View Article and Find Full Text PDF

Background: Aromatic l-amino acid decarboxylase deficiency (AADCD) is a rare, early-onset, dyskinetic encephalopathy mostly reflecting a defective synthesis of brain dopamine and serotonin. Intracerebral gene delivery (GD) provided a significant improvement among AADCD patients (mean age, ≤6 years).

Objective: We describe the clinical, biological, and imaging evolution of two AADCD patients ages >10 years after GD.

View Article and Find Full Text PDF

Background And Objective: GLUT1 deficiency syndrome (Glut1DS) is a treatable neurometabolic disease that causes a wide range of neurologic symptoms in children and adults. However, its diagnosis relies on an invasive test, that is, a lumbar puncture (LP) to measure glycorrhachia, and sometimes complex molecular analyses of the gene. This procedure limits the number of patients able to receive the standard of care.

View Article and Find Full Text PDF

Aim: To identify subtypes of developmental coordination disorder (DCD) in children.

Method: Children with DCD diagnosed through comprehensive evaluation at Robert-Debré Children's University Hospital (Paris, France) were consecutively enrolled from February 2017 to March 2020. We performed an unsupervised hierarchical clustering based on principal component analysis using a large set of variables encompassing cognitive, motor, and visuospatial scores (Wechsler Intelligence Scale for Children, Fifth Edition; Developmental Neuropsychological Assessment, Second Edition; Movement Assessment Battery for Children, Second Edition).

View Article and Find Full Text PDF

Heterozygous pathogenic variants in DNM1 cause developmental and epileptic encephalopathy (DEE) as a result of a dominant-negative mechanism impeding vesicular fission. Thus far, pathogenic variants in DNM1 have been studied with a canonical transcript that includes the alternatively spliced exon 10b. However, after performing RNA sequencing in 39 pediatric brain samples, we find the primary transcript expressed in the brain includes the downstream exon 10a instead.

View Article and Find Full Text PDF
Article Synopsis
  • ADCY5-related dyskinesia is an early-onset movement disorder without an established treatment, but there's anecdotal evidence suggesting caffeine may help improve symptoms.
  • A worldwide study involving 30 patients indicated that caffeine was well tolerated, with 87% reporting symptom improvement, including reduced movement disorder frequency and enhanced quality of life.
  • The study concludes that caffeine could be a viable first-line treatment option for patients with ADCY5-related dyskinesia.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the role of the cerebellum in paroxysmal kinesigenic dyskinesia (PKD), a condition causing involuntary movements, highlighting the limited understanding of its underlying mechanisms.
  • Twenty-two patients with a specific genetic variant and matched controls participated in a comprehensive neuroimaging study to assess brain structures and connections related to PKD.
  • Results showed significant gray and white matter changes in the cerebellum and other related brain areas, with cerebellar stimulation improving the communication within motor networks, suggesting a potential therapeutic avenue.
View Article and Find Full Text PDF

Purpose: Biallelic loss-of-function variants in ST3GAL5 cause GM3 synthase deficiency (GM3SD) responsible for Amish infantile epilepsy syndrome. All Amish patients carry the homozygous p.(Arg288Ter) variant arising from a founder effect.

View Article and Find Full Text PDF

Aicardi-Goutières syndrome (AGS) is a rare genetic neuroinflammatory disorder caused by abnormal upregulation of type 1 interferon signalling. Opsoclonus-myoclonus syndrome is a rare autoimmune phenotype demonstrating a disturbance in the humoral immune response mostly seen in the context of paraneoplastic or postinfectious states, although its pathophysiology is incompletely understood. We report the first three children described with AGS demonstrating transient opsoclonus and myoclonus after irritability and/or developmental regression, suggesting a pathological association.

View Article and Find Full Text PDF

Movement disorders in children. The phenomenological spectrum of pediatric movement disorders is wide and correspond to a large variety of causes. It comprises fixed transient, and progressive disorders.

View Article and Find Full Text PDF

Nucleotide excision repair associated diseases comprise overlapping phenotypes and a wide range of outcomes. The early stages still remain under-investigated and underdiagnosed, even although an early recognition of the first symptoms is of utmost importance for appropriate care and genetic counseling. We systematically collected clinical and molecular data from the literature and from newly diagnosed NER patients with neurological impairment, presenting clinical symptoms before the age of 12 months, including foetal cases.

View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the effectiveness of Whole Exome Sequencing (WES) to identify genetic causes in patients with early-onset or familial dystonia, where traditional gene panel sequencing had low diagnostic rates.
  • The research involved 32 patients and found that WES identified causative genetic variants in 11 patients from 9 families, resulting in a 34.4% overall diagnostic rate, with higher success in complex dystonia cases.
  • The findings indicate that WES could significantly enhance diagnostic capabilities beyond gene panel sequencing, particularly for patients with associated intellectual disabilities, suggesting further research is needed to explore links between dystonia and other neurodevelopmental disorders.
View Article and Find Full Text PDF

Unlabelled: In some patients with GLUT1 deficiency syndrome (GLUT1-DS), the diagnosis can be difficult to reach. We report a child with 2 inherited mutations suggesting an autosomal recessive transmission of SLC2A1 mutations.

Methods: The child and her parents were explored with erythrocyte 3-O-methyl-d-Glucose uptake, glucose uptake in oocytes expressing GLUT1 with the gene mutations and measure of the expression of GLUT1 at the surface of the circulating red blood cells by flow cytometry (METAglut1™ test).

View Article and Find Full Text PDF

Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a rare autosomal recessive neuromuscular disorder characterized by progressive motor and respiratory decline during the first year of life. Early and late-onset cases have recently been reported, although not meeting the established diagnostic criteria, these cases have been genotyped. We thus conducted a national multicenter observational retrospective study to determine the prognosis of children with SMARD1 according to their phenotype.

View Article and Find Full Text PDF

Glucose transporter type 1 (GLUT1) deficiency syndrome (GLUT1-DS) leads to a wide range of neurological symptoms. Ketogenic diets are very efficient to control epilepsy and movement disorders. We tested a novel simple and rapid blood test in 30 patients with GLUT1-DS with predominant movement disorders, 18 patients with movement disorders attributed to other genetic defects, and 346 healthy controls.

View Article and Find Full Text PDF

Aim: Glucose transporter type 1 deficiency syndrome (GLUT1-DS) results from impaired glucose transport into the brain, and is treated with a ketogenic diet. A few reports have suggested effectiveness of treatment using the modified Atkins diet (MAD). We aimed to assess the efficacy of MAD as a treatment for GLUT1-DS.

View Article and Find Full Text PDF